Plain-English translation of NCT05917405 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is comparing two different chemotherapy regimens used to prepare your body before a stem cell transplant for acute myeloid leukemia. One regimen uses a medication called paired with , while the other uses paired with —both combined with a drug to help prevent transplant rejection. The goal is to determine whether the newer medication approach leads to better long-term survival and fewer cancer relapses.
Relapse (cancer coming back) remains the biggest threat to survival after a stem cell transplant for blood cancers. Researchers believe that using a newer, more powerful chemotherapy medication in the preparation regimen might better eliminate remaining leukemia cells and improve survival rates.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of the two chemotherapy regimens over about 6 days before your stem cell transplant. You'll receive intravenous infusions at a hospital or treatment center, and the study team will monitor your health closely during and after the transplant. Your participation will continue for 2 years after transplant, with regular follow-up visits to track your recovery, survival, and quality of life.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
France